Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety, and PK of Ascending Dosages of Moxidectin Versus Ivermectin Against Strongyloides Stercoralis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (≥ 18 years) infected with S. stercoralis~* Absence of major systemic illnesses~* Written informed consent signed by individual~Exclusion Criteria:~* Any abnormal medical conditions or chronic disease~* Negative diagnostic result for S. stercoralis~* No written informed consent by individual.~* Pregnant and lactating women.~* Recent use of anthelmintic drug (within past 4 weeks), attending other clinical trials during the study~* Known allergy to study medications (i.e. moxidectin, ivermectin)~* Currently taking medications with known interaction (i.e. for warfarin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Phase 2a - Arm A (Type: EXPERIMENTAL): 2 mg Moxidectin at day 0 administered orally
- Phase 2a - Arm B (Type: EXPERIMENTAL): 4 mg Moxidectin at day 0 administered orally
- Phase 2a - Arm C (Type: EXPERIMENTAL): 6 mg Moxidectin at day 0 administered orally
- Phase 2a - Arm D (Type: EXPERIMENTAL): 8 mg Moxidectin at day 0 administered orally
- Phase 2a - Arm E (Type: EXPERIMENTAL): 10 mg Moxidectin at day 0 administered orally
- Phase 2a - Arm F (Type: EXPERIMENTAL): 12 mg Moxidectin at day 0 administered orally
- Phase 2a - Arm G (Type: PLACEBO_COMPARATOR): matching Placebo tablet(s) at day 0 administered orally
- Phase 2b - Arm A (Type: EXPERIMENTAL): the recommended dose moxidectin (i.e. the most promising dosage identified in phase 2a; between 2-12 mg) at day 0 administered orally~+ Ivermectin placebo, corresponding to Phase 2b - Arm B
- Phase 2b - Arm B (Type: ACTIVE_COMPARATOR): 200 µg/kg ivermectin at day 0 administered orally~+ Moxidectin placebo, corresponding to Phase 2b - Arm A

Based on this trial design, predict the completion outcome and termination type (if applicable).